169 related articles for article (PubMed ID: 26844277)
21. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Bick U; Engel C; Krug B; Heindel W; Fallenberg EM; Rhiem K; Maintz D; Golatta M; Speiser D; Rjosk-Dendorfer D; Lämmer-Skarke I; Dietzel F; Schäfer KWF; Leinert E; Weigel S; Sauer S; Pertschy S; Hofmockel T; Hagert-Winkler A; Kast K; Quante A; Meindl A; Kiechle M; Loeffler M; Schmutzler RK;
Breast Cancer Res Treat; 2019 May; 175(1):217-228. PubMed ID: 30725383
[TBL] [Abstract][Full Text] [Related]
22. Familial pancreatic cancer: challenging diagnostic approach and therapeutic management.
Mastoraki A; Chatzimavridou-Grigoriadou V; Chatzipetrou V; Mastoraki S; Papanikolaou IS; Danias N; Smyrniotis V; Arkadopoulos N
J Gastrointest Cancer; 2014 Sep; 45(3):256-61. PubMed ID: 24756831
[TBL] [Abstract][Full Text] [Related]
23. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
24. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins M; Schutte M; Lu J; Moskaluk CA; Weinstein CL; Petersen GM; Yeo CJ; Jackson CE; Lynch HT; Hruban RH; Kern SE
Cancer Res; 1996 Dec; 56(23):5360-4. PubMed ID: 8968085
[TBL] [Abstract][Full Text] [Related]
25. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
26. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
Grann VR; Patel PR; Jacobson JS; Warner E; Heitjan DF; Ashby-Thompson M; Hershman DL; Neugut AI
Breast Cancer Res Treat; 2011 Feb; 125(3):837-47. PubMed ID: 20644999
[TBL] [Abstract][Full Text] [Related]
28. Online tool to guide decisions for BRCA1/2 mutation carriers.
Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
30. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Aslanian HR; Lee JH; Canto MI
Gastroenterology; 2020 Jul; 159(1):358-362. PubMed ID: 32416142
[TBL] [Abstract][Full Text] [Related]
31. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Mersch J; Jackson MA; Park M; Nebgen D; Peterson SK; Singletary C; Arun BK; Litton JK
Cancer; 2015 Jan; 121(2):269-75. PubMed ID: 25224030
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
[TBL] [Abstract][Full Text] [Related]
34. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.
Pandharipande PV; Heberle C; Dowling EC; Kong CY; Tramontano A; Perzan KE; Brugge W; Hur C
Radiology; 2015 Apr; 275(1):177-87. PubMed ID: 25393849
[TBL] [Abstract][Full Text] [Related]
35. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.
Mukherjee B; Delancey JO; Raskin L; Everett J; Jeter J; Begg CB; Orlow I; Berwick M; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Culver HA; Rosso S; Zanetti R; Kanetsky PA; From L; Gruber SB;
J Natl Cancer Inst; 2012 Jun; 104(12):953-6. PubMed ID: 22534780
[TBL] [Abstract][Full Text] [Related]
36. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
de Mestier L; Danset JB; Neuzillet C; Rebours V; Cros J; Soufir N; Hammel P
Endocr Relat Cancer; 2016 Oct; 23(10):T57-67. PubMed ID: 27511924
[TBL] [Abstract][Full Text] [Related]
39. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
40. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
